Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2019.0289


Emerging clinico-genomic trials and research on regulatory networks shape the new era of breast cancer precision medicine.

Prof. J. Fogel, PhD.


The new era of patient-centric spatiotemporal genomic trials has just begun. Moreover, the combination of Next-generation sequencing (NGS) including ChiP-seq and Hi-C technologies enable deeper exploration of aberrant regulatory networks. Single. These two emerging research directions could realize a medium term and long-term horizon for evidence –based development of biomarkers and targeted drugs as well as pharmaceutical controllability of perturbated circuits respectively.

(Citation: Gastric & Breast Cancer 2019; 14(1): 118-123)



You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 10 June 2019